Press Releases

Intercytex expands Executive Management team

Cambridge, UK, 10 July 2006 – Intercytex (LSE: ICX), the cell therapy company developing products for the advanced woundcare and aesthetic medicine markets, today announces the appointment of Jan Benschop as Vice President, Commercial Development.

Jan has over 25 years experience in the sales and marketing of pharmaceutical, healthcare and biological products working for a number of high-profile companies within the sector. He was previously General Manager, Europe and a VP of Elan Biopharmaceuticals involved in the pre-launch and launch of a number of biotechnology products. Prior to Elan, he was a Director of Allergan responsible for the European marketing of its skincare products including Botox®.

“I am delighted to welcome Jan to Intercytex,” said Nick Higgins, Chief Executive Officer. “He brings significant and highly relevant sales and marketing experience to Intercytex at a time when the company’s products are nearing commercialisation. Jan has a deep understanding of the aesthetic medicine market and his immediate priority will be to prepare for the launch of ICX-RHY, the company’s facial rejuvenation product, scheduled for the second half of 2007.”

Enquiries:

Intercytex
Nick Higgins, Chief Executive Officer: +44 (0)1223 421962

Financial Dynamics
David Yates/Anna Keeble: +44 (0)207 831 3113

About Intercytex:

Intercytex is an emerging healthcare company developing and commercialising cell therapy products for the woundcare and aesthetic medicine markets. Intercytex is using its proprietary expertise in cell therapy to develop products that harness the innate ability of human cells to regenerate and repair the body.

Intercytex has four products in development:

• ICX-PRO, designed actively to stimulate repair in chronic wounds in Phase III trials;
• ICX-SKN, being developed as a durable and robust skin replacement, due to start Phase I trials later this year;
• ICX-RHY, a facial rejuvenation product which is completing a Phase I clinical trial; and
• ICX-TRC, a hair regeneration product shortly to enter Phase II trials.

Note: In March of this year Intercytex received confirmation from the MHRA that ICX-RHY was outside the scope of the current legislation covering the marketing of medicines and devices in the UK. Intercytex plans to make ICX-RHY available in the UK market once additional clinical testing has been completed, estimated to be in the second half of 2007.

Intercytex commenced operations in 2000 and currently employs around 70 staff. In addition to its head office in Cambridge, UK, it has a GMP clinical production facility plus research and development laboratories in Manchester, UK. Additional laboratories are located in Boston, USA.

Intercytex’ shares were admitted for trading on the Alternative Investment Market of the London Stock Exchange on 1 February 2006 under the ticker symbol ICX.L.

For further information on Intercytex, please visit www.intercytex.com